📊 COSM Key Takeaways
Investment Thesis
Cosmos Health exhibits severe fundamental deterioration with negative profitability across all levels (operating margin -11.6%, net margin -19.7%) while generating negative free cash flow of -3.9M despite modest 2% revenue growth. The company's liquidity crisis is evident with a current ratio of 0.99x, minimal cash reserves of $889K, and negative operating cash flow, creating immediate solvency concerns for a wholesale drug distributor requiring substantial working capital.
COSM Strengths
- Modest revenue growth of 2.0% YoY demonstrates business persistence in challenging environment
- Moderate leverage with debt-to-equity ratio of 0.23x provides some balance sheet flexibility
- Gross margin of 12.8% is typical for wholesale pharmaceutical distribution sector
COSM Risks
- Severe liquidity crisis: current ratio of 0.99x with only $889K cash and negative operating cash flow creates imminent refinancing/covenant risk
- Persistent unprofitability: negative operating income of -$5.3M and net loss of -$9.0M indicate structural operational problems, not temporary headwinds
- Negative free cash flow of -$3.9M with FCF margin of -8.6% demonstrates unsustainable business model that burns cash despite revenue generation
- Interest coverage ratio of -4.3x indicates inability to service debt from operations, forcing reliance on asset depletion or external financing
Key Metrics to Watch
- Quarterly operating cash flow trend and path to positive OCF
- Cash balance and burn rate relative to available liquidity facilities
- Gross margin stability and operating expense control initiatives
- Working capital management efficiency (accounts receivable and inventory turns)
COSM Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
COSM Profitability Ratios
COSM vs Default Sector
How Cosmos Health Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
COSM Balance Sheet & Liquidity
COSM 5-Year Financial Trend
5-Year Trend Summary: Cosmos Health Inc.'s revenue has remained relatively flat over the 5-year period, with a 2% decline. The most recent EPS of $-2.15 indicates the company is currently unprofitable.
COSM Growth Metrics (YoY)
COSM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $12.4M | -$5.4M | $-0.17 |
| Q2 2025 | $13.2M | -$2.6M | $-0.10 |
| Q1 2025 | $13.7M | -$818.1K | $-0.03 |
| Q3 2024 | $12.4M | -$459.9K | $-0.27 |
| Q2 2024 | $12.4M | -$459.9K | $-0.09 |
| Q1 2024 | $12.3M | -$459.9K | $-0.04 |
| Q3 2023 | $12.0M | $203.3K | $-0.27 |
| Q2 2023 | $12.4M | $203.3K | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
COSM Capital Allocation
COSM SEC Filings
Access official SEC EDGAR filings for Cosmos Health Inc. (CIK: 0001474167)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COSM
What is the AI rating for COSM?
Cosmos Health Inc. (COSM) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are COSM's key strengths?
Modest revenue growth of 2.0% YoY demonstrates business persistence in challenging environment. Moderate leverage with debt-to-equity ratio of 0.23x provides some balance sheet flexibility.
What are the risks of investing in COSM?
Severe liquidity crisis: current ratio of 0.99x with only $889K cash and negative operating cash flow creates imminent refinancing/covenant risk. Persistent unprofitability: negative operating income of -$5.3M and net loss of -$9.0M indicate structural operational problems, not temporary headwinds.
What is COSM's revenue and growth?
Cosmos Health Inc. reported revenue of $45.6M.
Does COSM pay dividends?
Cosmos Health Inc. does not currently pay dividends.
Where can I find COSM SEC filings?
Official SEC filings for Cosmos Health Inc. (CIK: 0001474167) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COSM's EPS?
Cosmos Health Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.